Evidence map›Paper›PMID 40788779›Full record

ArticleAging cell2025

Oxytocin Enhances Demethylation Through TET Enzyme Expression in Neurons of Aged Mice: Oxytocin as a Potential Antiaging Peptide.

Yuko Maejima, Shoko Yokota, Megumi Yamachi, Shizu Hidema, Tomoyuki Ono, Shu Taira, Katsuhiko Nishimori, Heidi de Wet, Kenju Shimomura

Abstract readEvaluation Study
In one paragraph

Article in Aging cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Yuko MaejimaDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.ORCID 0000-0001-5370-5758
Shoko YokotaDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Megumi YamachiDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shizu HidemaDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Tomoyuki OnoDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.
Shu TairaFaculty of Food and Agricultural Sciences, Fukushima University, Fukushima, Japan.
Katsuhiko NishimoriDepartments of Obesity and Inflammation Research, Fukushima Medical University School of Medicine, Fukushima, Japan.
Heidi de WetDepartment of Physiology, Anatomy and Genetics, Sherrington Building, University of Oxford, Oxford, UK.ORCID 0000-0002-9871-6909
Kenju ShimomuraDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan.

Funding

Japan Society for the Promotion of Science 18K08483Japan Society for the Promotion of Science 22K11755Japan Society for the Promotion of Science 23K08012Japan Society for the Promotion of Science 25K14793
6 · The paper itself

Abstract

While it is well-documented that plasma oxytocin (OXT) levels decline with age, the underlying mechanisms remain elusive. This study aimed to elucidate the physiological mechanisms contributing to this age-related decrease in plasma OXT and the possible use of OXT supplementation on improving age-related decline of neural function. Comparing young (9 weeks) and aged (> 45 weeks) mice, aged mice showed reduced plasma OXT levels, an increase in the inflammation marker hs-CRP, and decreased OXT-positive neurons in the hypothalamus. Aged mice showed signs of epigenetic changes in the hypothalamus as indicated by decreased ten-eleven translocation (TET) family mRNA expression, decreased 5-hydroxymethylcytosine (5hmC) positive neurons, and downregulated mitochondrial respiratory complex IV (COX IV) expression. Nasal application of OXT (10 μg/day) for 10 days to aged mice resulted in normalized plasma OXT and inflammation levels and a recovery of OXT-positive neurons, TET2 mRNA levels, 5hmC positive neurons, and COX IV expression. Directly confirming a role for OXTR signaling, TET2, COX IV, and 5hmC in the hypothalamus and hippocampus were also found to be decreased in oxytocin receptor (OXTR) null mice, compared with age-matched WT mice. Furthermore, we show that methylation as a result of aging decreases OXT production in hypothalamic neurons, thereby reducing circulating plasma OXT levels, which can be reversed by nasal OXT treatment. The data presented here suggest that aging, DNA methylation, mitochondrial dysfunction, inflammation, and senescence are interconnected in a vicious cycle, which can be successfully interrupted by OXT treatment.

Indexed as

AgingDNA-Binding ProteinsNeuronsOxytocinProto-Oncogene ProteinsAnimalsDemethylationDioxygenasesHypothalamusMaleMiceMice, Inbred C57BLReceptors, OxytocinDioxygenasesDNA-Binding ProteinsOxytocinProto-Oncogene ProteinsReceptors, OxytocinTet2 protein, mouseantiagingmethylationmitochondrianeuronsoxytocinTET enzyme

Identifiers

PMID40788779
PMCPMC12507420

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.